{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T11:16:21Z","timestamp":1782818181080,"version":"3.54.5"},"reference-count":49,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["093"],"award-info":[{"award-number":["093"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005570","name":"Takeda Pharmaceuticals North America","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005570","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.jacl.2020.12.010","type":"journal-article","created":{"date-parts":[[2020,12,27]],"date-time":"2020-12-27T09:33:59Z","timestamp":1609061639000},"page":"275-291","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Interrogation of selected genes influencing serum LDL-Cholesterol levels in patients with well characterized NAFLD"],"prefix":"10.1016","volume":"15","author":[{"given":"Eduardo","family":"Vilar-Gomez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2056-4909","authenticated-orcid":false,"given":"Samer","family":"Gawrieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiebing","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7836-5187","authenticated-orcid":false,"given":"Adam D.","family":"McIntyre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Hegele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naga","family":"Chalasani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2020.12.010_bib1","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41575-019-0212-0","article-title":"Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology","volume":"17","author":"Eslam","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jacl.2020.12.010_bib2","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jacl.2020.12.010_bib3","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cmet.2019.12.002","article-title":"Leveraging human genetics to identify potential new treatments for fatty liver disease","volume":"31","author":"Romeo","year":"2020","journal-title":"Cell Metabol"},{"key":"10.1016\/j.jacl.2020.12.010_bib4","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/MOL.0000000000000072","article-title":"Hypobetalipoproteinemia and abetalipoproteinemia","volume":"25","author":"Welty","year":"2014","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.jacl.2020.12.010_bib5","doi-asserted-by":"crossref","first-page":"e002376","DOI":"10.1161\/CIRCGEN.118.002376","article-title":"Rare protein-truncating variants in APOB, lower low-density lipoprotein cholesterol, and protection against coronary heart disease","volume":"12","author":"Peloso","year":"2019","journal-title":"Circ Genom Precis Med"},{"key":"10.1016\/j.jacl.2020.12.010_bib6","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1007\/s00125-011-2157-x","article-title":"Hepatic steatosis does not cause insulin resistance in people with familial hypobetalipoproteinaemia","volume":"54","author":"Visser","year":"2011","journal-title":"Diabetologia"},{"key":"10.1016\/j.jacl.2020.12.010_bib7","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/B978-0-12-387025-4.00004-2","article-title":"Hypobetalipoproteinemia: genetics, biochemistry, and clinical spectrum","volume":"54","author":"Tarugi","year":"2011","journal-title":"Adv Clin Chem"},{"key":"10.1016\/j.jacl.2020.12.010_bib8","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/S0022-2275(20)37582-9","article-title":"Positive linear correlation between the length of truncated apolipoprotein B and its secretion rate: in\u00a0vivo studies in human apoB-89, apoB-75, apoB-54.8, and apoB-31 heterozygotes","volume":"37","author":"Parhofer","year":"1996","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2020.12.010_bib9","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1161\/01.ATV.19.11.2714","article-title":"Decreased production rates of VLDL triglycerides and ApoB-100 in subjects heterozygous for familial hypobetalipoproteinemia","volume":"19","author":"Elias","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2020.12.010_bib10","first-page":"1","article-title":"Triglyceride metabolism in the liver","volume":"8","author":"Alves-Bezerra","year":"2017","journal-title":"Comp Physiol"},{"key":"10.1016\/j.jacl.2020.12.010_bib11","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ymgme.2008.10.016","article-title":"Functional analysis of two novel splice site mutations of APOB gene in familial hypobetalipoproteinemia","volume":"96","author":"Di Leo","year":"2009","journal-title":"Mol Genet Metabol"},{"key":"10.1016\/j.jacl.2020.12.010_bib12","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1373\/clinchem.2004.037978","article-title":"Liver dysfunction and steatosis in familial hypobetalipoproteinemia","volume":"51","author":"Whitfield","year":"2005","journal-title":"Clin Chem"},{"key":"10.1016\/j.jacl.2020.12.010_bib13","doi-asserted-by":"crossref","first-page":"178","DOI":"10.7555\/JBR.28.20140019","article-title":"Apolipoprotein B100 quality control and the regulation of hepatic very low density lipoprotein secretion","volume":"28","author":"Fisher","year":"2014","journal-title":"J Biomed Res"},{"key":"10.1016\/j.jacl.2020.12.010_bib14","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1038\/s41598-019-39998-2","article-title":"Rare pathogenic variants predispose to hepatocellular carcinoma in nonalcoholic fatty liver disease","volume":"9","author":"Pelusi","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.jacl.2020.12.010_bib15","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/MOL.0000000000000663","article-title":"Hypobetalipoproteinemia and abetalipoproteinemia: liver disease and cardiovascular disease","volume":"31","author":"Welty","year":"2020","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.jacl.2020.12.010_bib16","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/ng.257","article-title":"Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease","volume":"40","author":"Romeo","year":"2008","journal-title":"Nat Genet"},{"key":"10.1016\/j.jacl.2020.12.010_bib17","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/hep.27556","article-title":"Genetic variation in transmembrane 6 superfamily member 2 and the risk of nonalcoholic fatty liver disease and histological disease severity","volume":"61","author":"Sookoian","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jacl.2020.12.010_bib18","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1002\/hep.30350","article-title":"17-Beta hydroxysteroid dehydrogenase 13 is a hepatic retinol dehydrogenase associated with histological features of nonalcoholic fatty liver disease","volume":"69","author":"Ma","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jacl.2020.12.010_bib19","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jhep.2020.08.027","article-title":"rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: a meta-analysis","volume":"74","author":"Teo","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.jacl.2020.12.010_bib20","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/hep.24806","article-title":"Variant in the glucokinase regulatory protein (GCKR) gene is associated with fatty liver in obese children and adolescents","volume":"55","author":"Santoro","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jacl.2020.12.010_bib21","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/ng.2901","article-title":"Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease","volume":"46","author":"Kozlitina","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.jacl.2020.12.010_bib22","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/hep.30874","article-title":"Apolipoprotein B and PNPLA3 double heterozygosity in a father-son pair with advanced nonalcoholic fatty liver disease","volume":"71","author":"Jansson-Knodell","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jacl.2020.12.010_bib23","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1002\/hep.24283","article-title":"Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease","volume":"53","author":"Sookoian","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jacl.2020.12.010_bib24","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/hep.23784","article-title":"Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease","volume":"52","author":"Neuschwander-Tetri","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jacl.2020.12.010_bib25","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2020.12.010_bib26","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2020.12.010_bib27","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1093\/hmg\/ddt573","article-title":"Novel functional APOB mutations outside LDL-binding region causing familial hypercholesterolaemia","volume":"23","author":"Alves","year":"2014","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.jacl.2020.12.010_bib28","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.jacl.2020.12.010_bib29","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/MOL.0000000000000163","article-title":"Targeted next-generation sequencing in monogenic dyslipidemias","volume":"26","author":"Hegele","year":"2015","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.jacl.2020.12.010_bib30","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1161\/ATVBAHA.116.308027","article-title":"Polygenic versus monogenic causes of hypercholesterolemia ascertained clinically","volume":"36","author":"Wang","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2020.12.010_bib31","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cjco.2019.01.003","article-title":"Clinical utility and practical considerations of a coronary artery disease genetic risk score","volume":"1","author":"Liu","year":"2019","journal-title":"CJC Open"},{"key":"10.1016\/j.jacl.2020.12.010_bib32","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.atherosclerosis.2013.09.007","article-title":"APOE p.Leu167del mutation in familial hypercholesterolemia","volume":"231","author":"Awan","year":"2013","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2020.12.010_bib33","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1365-2265.2012.04498.x","article-title":"Fatty liver and insulin resistance in children with hypobetalipoproteinemia: the importance of aetiology","volume":"79","author":"Della Corte","year":"2013","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.jacl.2020.12.010_bib34","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s00592-016-0931-4","article-title":"Association between familial hypobetalipoproteinemia and the risk of diabetes. Is this the other side of the cholesterol-diabetes connection? A systematic review of literature","volume":"54","author":"Noto","year":"2017","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.jacl.2020.12.010_bib35","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1053\/j.gastro.2016.01.032","article-title":"The MBOAT7-TMC4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of European descent","volume":"150","author":"Mancina","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jacl.2020.12.010_bib36","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1194\/jlr.M200342-JLR200","article-title":"Fatty liver in familial hypobetalipoproteinemia: triglyceride assembly into VLDL particles is affected by the extent of hepatic steatosis","volume":"44","author":"Schonfeld","year":"2003","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2020.12.010_bib37","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1016\/j.jacc.2013.07.081","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial","volume":"62","author":"Thomas","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2020.12.010_bib38","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1194\/jlr.M002915","article-title":"Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia","volume":"51","author":"Visser","year":"2010","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2020.12.010_bib39","doi-asserted-by":"crossref","first-page":"e001632","DOI":"10.1161\/CIRCGENETICS.116.001632","article-title":"PCSK9 loss-of-function variants, low-density lipoprotein cholesterol, and risk of coronary heart disease and stroke: data from 9 studies of blacks and whites","volume":"10","author":"Kent","year":"2017","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.jacl.2020.12.010_bib40","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1194\/jlr.R300002-JLR200","article-title":"Familial hypobetalipoproteinemia: a review","volume":"44","author":"Schonfeld","year":"2003","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2020.12.010_bib41","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1194\/jlr.M300275-JLR200","article-title":"Hepatic secretion of apoB-100 is impaired in hypobetalipoproteinemic mice with an apoB-38.9-specifying allele","volume":"45","author":"Chen","year":"2004","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2020.12.010_bib42","doi-asserted-by":"crossref","first-page":"14135","DOI":"10.1074\/jbc.M200617200","article-title":"Hypobetalipoproteinemic mice with a targeted apolipoprotein (Apo) B-27.6-specifying mutation: in\u00a0vivo evidence for an important role of amino acids 1254-1744 of ApoB in lipid transport and metabolism of the apoB-containing lipoprotein","volume":"277","author":"Chen","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jacl.2020.12.010_bib43","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/MEG.0b013e3282ffd9f8","article-title":"Cryptogenic cirrhosis in a patient with familial hypocholesterolemia due to a new truncated form of apolipoprotein B","volume":"21","author":"Bonnefont-Rousselot","year":"2009","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jacl.2020.12.010_bib44","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1023\/A:1026646618643","article-title":"Familial heterozygous hypobetalipoproteinemia, extrahepatic primary malignancy, and hepatocellular carcinoma","volume":"43","author":"Lonardo","year":"1998","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jacl.2020.12.010_bib45","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1086\/500615","article-title":"A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol","volume":"78","author":"Kotowski","year":"2006","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.jacl.2020.12.010_bib46","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2020.12.010_bib47","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/hep.22354","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration","volume":"48","author":"Zaid","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jacl.2020.12.010_bib48","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41569-018-0052-6","article-title":"The complex molecular genetics of familial hypercholesterolaemia","volume":"16","author":"Berberich","year":"2019","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jacl.2020.12.010_bib49","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1093\/eurheartj\/ehw028","article-title":"Mutations causative of familial hypercholesterolaemia: screening of 98 098 individuals from the Copenhagen General Population Study estimated a prevalence of 1 in 217","volume":"37","author":"Benn","year":"2016","journal-title":"Eur Heart J"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287420303470?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287420303470?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T13:36:19Z","timestamp":1761831379000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287420303470"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S1933287420303470"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2020.12.010","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interrogation of selected genes influencing serum LDL-Cholesterol levels in patients with well characterized NAFLD","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2020.12.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Inc. on behalf of National Lipid Association.","name":"copyright","label":"Copyright"}]}}